Jago Grahak Jago

Edit Template

Blog

Your blog category

Playtime or Poison? Harmful & toxic toys in Indian markets

PM Modi’s Call for Safe, Indigenous Toys At the India Toy Fair 2021, Prime Minister Narendra Modi urged manufacturers to “make toys that are better for ecology and psychology,” stressing the need for eco-friendly materials, innovation, and self-reliance. He reminded the nation that toys are not trivial—they shape childhood imagination and national identity. In his Independence Day 2024 address, he reiterated that India must not depend on unsafe imports, calling for an Aatmanirbhar Bharat in toys. Yet, despite these warnings, India’s toy market remains dangerously unregulated. Raids, recalls, and seizures continue to expose lead-laden, chemically hazardous, and mechanically unsafe toys flooding shelves and online platforms. The Reality: Unsafe Toys Everywhere Recent enforcement actions reveal the scale of the crisis. Toys with excessive lead, phthalates, and explosion-prone batteries have been confiscated across India. Many were imported illegally, while others were domestically produced with recycled plastics and uncertified dyes. Parents, often lured by low prices, unknowingly expose children to hidden toxins. The result is a silent public health emergency: lead poisoning, hormonal disruption, and fire hazards—all wrapped in bright packaging. Raids and Recalls (2023–2025) Year Location Action Taken Hazard Identified Outcome 2023 Nhava Sheva Port (Mumbai) Customs seizure of Chinese toy consignments Lead paint, phthalates Thousands of toys destroyed; importers fined 2024 Bengaluru & Chennai Product recalls of battery-operated toys Exploding lithium cells Toys pulled from shelves; BIS issued safety alert 2024 Delhi NCR Market raids on local shops Uncertified plastic dolls, choking hazards Hundreds of toys confiscated; traders penalized 2025 Mumbai & Pune Raids on wholesale warehouses Excessive lead, toxic dyes Large consignments seized; criminal cases filed 2025 Online marketplaces Crackdown on uncertified imports No BIS certification, chemical hazards Listings removed; platforms warned of liability Why the Market Is Vulnerable India’s toy sector suffers from weak enforcement of BIS standards, consumer ignorance, and e-commerce loopholes. While BIS certification is mandatory, enforcement is patchy. Small traders bypass rules, importing toys without safety checks. Online platforms, meanwhile, are flooded with uncertified toys shipped directly from overseas sellers. Even domestic manufacturers cut corners, using recycled plastics and uncertified dyes to lower costs. The result is a market where unsafe toys are not the exception but the norm. The Consumer Cost Unsafe toys are not just a regulatory issue—they are a public health crisis. Lead poisoning can cause irreversible brain damage, phthalates disrupt hormones, and faulty batteries pose fire hazards. Children, the most vulnerable consumers, are being exposed daily to risks hidden inside brightly coloured playthings. The World Health Organization has repeatedly warned that no level of lead exposure is safe for children. Yet raids in India continue to uncover toys with lead levels far above permissible limits. Modi’s Vision vs. Market Reality Prime Minister Modi’s speeches have consistently highlighted toys as a sector where India can combine cultural heritage with modern innovation. He has called for toys that reflect India’s traditions, use eco-friendly materials, and meet global safety standards. But the reality is starkly different. The market is flooded with cheap imports that undermine both consumer trust and national pride. Domestic manufacturers, instead of rising to the challenge, often cut corners to compete on price. The gap between vision and reality is widening. What Needs to Change India must act decisively: Stricter Enforcement: Customs and state regulators must intensify raids and impose heavy penalties on violators. Consumer Awareness Campaigns: Parents must be educated to check for ISI/BIS marks and avoid suspiciously cheap imports. Industry Accountability: Domestic manufacturers must invest in safe, eco-friendly materials, aligning with Modi’s vision of an Aatmanirbhar Bharat toy industry. E-commerce Regulation: Platforms must be held liable for selling uncertified toys, with mandatory compliance checks. Call to Action India’s toy industry sits at a crossroads. On one side lies Prime Minister Modi’s vision of a self-reliant, eco-friendly sector that safeguards children. On the other lies the grim reality of toxic imports and unsafe domestic products flooding the market. The choice is stark: either India enforces its standards and protects its youngest citizens, or it risks turning playtime into a silent health hazard. For consumers, vigilance is the first line of defence. For regulators, decisive enforcement is overdue. A good toy should spark imagination—not endanger life. India must act now to ensure that every toy in a child’s hand is safe, sustainable, and proudly made to protect the future. 5 Things Parents Must Check Before Buying a Toy 1. Look for the BIS/ISI Mark Always check if the toy carries the Bureau of Indian Standards (BIS) certification. This mark ensures the toy has passed safety tests for chemicals, choking hazards, and mechanical risks. 2. Avoid Suspiciously Cheap Imports If the price seems too good to be true, it probably is. Ultra-cheap toys often bypass safety standards and may contain toxic paints, recycled plastics, or faulty batteries. 3. Check Labels and Packaging Read the packaging carefully. Safe toys should list the manufacturer’s details, age-appropriateness, and safety warnings. Avoid toys with missing or vague labels. 4. Be Wary of Online Marketplaces Many uncertified toys slip through e-commerce platforms. Buy only from trusted sellers and check product reviews. If the toy lacks BIS certification, don’t add it to your cart. 5. Inspect Before Play Before handing a toy to your child, inspect it for sharp edges, loose parts, or strong chemical smells. If it looks flimsy or smells of chemicals, it’s not safe.

Playtime or Poison? Harmful & toxic toys in Indian markets Read More »

India waives clinical trial requirement for drugs approved in developed markets

August 08,2024 New Delhi: The government has done away with the requirement of clinical investigation for new drugs having significant therapeutic advance over the current standard care and have already got the regulatory approval in the US, UK, Japan, Australia, Canada or the European Union. Clinical trial waivers will also be considered for new drugs for rare diseases, drugs used in pandemic situations or for special defence purposes, and gene and cellular therapy products that are approved in these developed markets, the Central Drugs Standard Control Organisation (CDSCO) said in a circular on Wednesday. The decision is aimed at speeding up the availability of new drugs and medical devices in the country. As reported by ET last week, India had previously given such waivers only for drugs and medical devices that have got regulatory clearance in the US, UK, Australia, Canada and Japan. Now the local drug regulator added the EU also to the list, people in the know told ET. Addition of the EU for the clinical trial waiver has been under consideration since 2018 when, during a meeting of the India-EU sub-commission on trade, EU officials raised the issue. After this, a proposal to include the EU for medical devices was sent to the health ministry. However, it was referred back to the CDSCO for critical review in the context of updated rules and recent notifications. The ministry also asked for deliberations in consultation with the Drug Technical Advisory Board for a fresh proposal. Rajiv Nath, forum coordinator of the Association of Indian Medical Devices Industry, told ET earlier that if India needed to give EU-based manufacturers any waiver or fast-track regulatory approval, then the country should negotiate its trade agreement with the EU on a reciprocal basis rather than simply conceding and amending its Medical Devices Rules. Source: Healthworld

India waives clinical trial requirement for drugs approved in developed markets Read More »

Wegovy, Ozempic linked with sight-threatening eye disorder in study

July 04,2024 London: Patients using Novo Nordisk’s wildly popular weigh-loss drug Wegovy and its similar medicines for type 2 diabetes may be at increased risk for a sight-threatening eye condition, according to data from a study published on Wednesday. Wegovy and Novo’s diabetes drugs Ozempic and Rybelsus all contain the same active ingredient, semaglutide, and belong to a class of medications known as GLP1 receptor agonists. The rate of the eye problem known as nonarteritic anterior ischemic optic neuropathy, or NAION, was 8.9% for those taking semaglutide for type 2 diabetes, compared with 1.8% for patients taking non-GLP-1 diabetes medications, researchers reported in JAMA Ophthalmology. Among those prescribed semaglutide for overweight or obesity, the rate of the eye condition was 6.7%, versus 0.8% for those receiving other types of medications for weight reduction. The 36-month observational study involved 710 adults with type 2 diabetes and 979 taking medications for weight loss. NAION develops from insufficient blood flow to the optic nerve and causes sudden painless vision loss in one eye. It is the second most common cause of blindness due to optic nerve damage, after glaucoma. After taking patients’ other risk factors for the condition into account, such as high blood pressure and obstructive sleep apnea, use of semaglutide was associated with a more than four times higher risk of NAION in those receiving it for diabetes and a more than seven times higher risk in patients taking it for obesity. Novo Nordisk in an emailed statement noted several limitations of the study design, which was not a randomized controlled trial. “Overall, the data published in the study is not sufficient to establish a causal association between GLP-1 receptor agonist use and NAION,” the Danish drugmaker said, adding that the condition “is not an adverse drug reaction for the marketed formulations of semaglutide.” NAION more often affects older individuals. In the overall U.S. population, the estimated annual incidence is 0.54 per 100,000 people, rising to 2.3 to 10.2 per 100,000 in adults above age 50, according to the American Academy of Ophthalmology. The prognosis for visual recovery is better for younger patients, the AAO says. Mean ages in the study were 46 among patients using semaglutide for obesity and 57 among those using it for diabetes. “This work has been carried out to a high level of quality and… does suggest an association between semaglutide treatment and one form of sight-threatening optic neuropathy, but this would ideally be tested in larger studies,” Graham McGeown of Queen’s University Belfast, who studies diabetic eye disease but was not involved in the new research, said in a statement. “Given the rapid increase in semaglutide use and its possible licensing for a range of problems other than obesity and type-2 diabetes, this issue deserves further study, but possible drug side effects always need to be balanced against likely benefits,” McGeown said. The researchers involved in the study were not immediately available to comment on their findings. Source: Healthworld

Wegovy, Ozempic linked with sight-threatening eye disorder in study Read More »

Who governs ‘surrogate ads’ for alcohol?

New Delhi, May 13: Mineral water, sodas, music and sports franchises are among the common avenues taken by alcohol manufacturers to advertise their brands. So what is new in this? Nothing. But what is befuddling those in power as well as the moral police is how ‘surrogate advertising’ can be monitored in the absence of overarching legislation. At the Centre, the buck is passed on between ministries and sometimes to respective States. This is even as consumer activists urging the Government to frame a central legislation, even if effective implementation will rest with the State Governments. In fact, the self-regulating Advertising Standards Council of India (ASCI) already has a code on brand extension. “Surrogate advertising is not allowed as per law but we have been urging the Government to start taking legal action against liquor brands that violate these providers and are habitual offenders,” said Bejon Misra, Founder, Consumer Online Foundation. Regulation of such advertising appeared to fall under the jurisdiction of at least five Ministries – Consumer Affairs, Health, Information & Broadcasting (I&B), IT and Social Justice and Empowerment. “There are ambiguous court rulings on the matter where alcohol manufacturers state that the logo is the identity of the brand and using it on products other than alcohol is a legitimate business activity. So it’s mainly down to legal interpretation and in time will need to be settled by courts to establish a stated position,” a senior Government official told BusinessLine. He added any concerted effort to clamp down on the practice would have to be led by the Health Ministry, which took the lead in curbing cigarette/tobacco advertising. Another official pointed out that Section 2(r) of the Consumer Protection Act, 1986 outlined ‘unfair trade practices’ for sales maximisation of a good or service and provided legal recourse for consumers if suppliers were found to have engaged in misleading advertisements. “Though it does not explicitly mention surrogate advertising, sellers could be prosecuted depending on how a case is presented. That said, if mineral water advertised by an alcohol company meets requisite standards, it’s a murky area,” he said, adding new legislation might not serve any purpose and could lead to inter-sectoral conflicts. Direct advertising of alcoholic beverages is banned in India but private channels have often permitted surrogate advertising. “We need to have a comprehensive Central Law that regulates various aspects of alcohol consumption and promotion,” said Monika Arora, Health Promotion & Associate Professor, Public Health Foundation of India. http://www.thehindubusinessline.com/companies/who-governs-surrogate-ads-for-alcohol/article7202285.ece

Who governs ‘surrogate ads’ for alcohol? Read More »